Form 4: Rhythm Pharmaceuticals Executive Sells Shares

Sentiment:

Insider Transaction (Form 4)


Alastair Garfield, Chief Scientific Officer of Rhythm Pharmaceuticals, Inc., sold 7,763 shares of common stock on August 13, 2026.

Summary

  • Open-market sale: disposed of 2,007 Common Stock at $116.11 ($233,031) on August 13, 2026; holds 8,051 after (Direct).
  • Open-market sale: disposed of 1,556 Common Stock at $117.08 ($182,170) on August 13, 2026; holds 6,495 after (Direct).
  • Open-market sale: disposed of 3,400 Common Stock at $118.28 ($402,167) on August 13, 2026; holds 3,095 after (Direct).
  • Open-market sale: disposed of 800 Common Stock at $119.17 ($95,335) on August 13, 2026; holds 2,295 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $912,703 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Alastair Garfield β€” Officer (Chief Scientific Officer)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-08-13Open-market saleCommon Stock2,007$116$233.0K8,051
2026-08-13Open-market saleCommon Stock1,556$117$182.2K6,495
2026-08-13Open-market saleCommon Stock3,400$118$402.2K3,095
2026-08-13Open-market saleCommon Stock800$119$95.3K2,295

Key Dates

DateDescription
2026-08-13Open-market sale (2,007 shares)
2026-08-13Open-market sale (1,556 shares)
2026-08-13Open-market sale (3,400 shares)
2026-08-13Open-market sale (800 shares)

Keywords

insider transaction, Form 4, RYTM, RHYTHM PHARMACEUTICALS, INC., bearish, Alastair Garfield

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.